Nektar Therapeutics Lands $373.8 Million in Public Offering

Event summary

  • Nektar Therapeutics completed a public offering of common stock, raising approximately $373.8 million in gross proceeds.
  • The offering consisted of 4,062,500 shares, including 529,891 shares purchased by underwriters through the exercise of an over-allotment option.
  • The shares were priced at $92.00 per share.
  • Jefferies, TD Cowen, Piper Sandler, and Citigroup served as joint bookrunning managers for the offering.
  • The offering was conducted under a shelf registration statement filed with the SEC on November 12, 2025.

The big picture

Nektar's successful offering underscores the continued investor appetite for clinical-stage biotechnology companies with promising immunology therapies. The substantial capital raise provides a significant runway for clinical development, but also increases the pressure to deliver positive clinical data and demonstrate a clear path to commercialization. The offering's size suggests a degree of confidence in Nektar's pipeline, but also highlights the need for disciplined execution to justify the valuation.

What we're watching

Capital Allocation
The influx of capital will likely accelerate Nektar’s clinical trial timelines for rezpegaldesleukin and other pipeline candidates, but investors should monitor burn rate and the efficiency of resource deployment.
Share Dilution
The significant share increase will dilute existing shareholders; the market's reaction will depend on whether Nektar can demonstrate meaningful clinical progress and value creation to offset the dilution.
Clinical Trial Data
The success of rezpegaldesleukin in ongoing Phase 2b trials for atopic dermatitis, alopecia areata, and Type 1 diabetes will be critical in justifying the valuation and attracting further investment.

Related topics

Biotechnology